線粒體質(zhì)量控制在阿霉素誘導(dǎo)的心臟毒性中的研究進展

打開文本圖片集

Mitochondrial Quality Control in Doxorubicin Cardiotoxicity

WANG Xinyu1，WANG Yuqi1，LUO Haowen1，CHANG Pan ，ZHAO Xiaohong1 （1.DepartmentofAnesthesia，Second Clinical Medical Colege，Xi’an Medical University，Xi’an7O38，Shaanxi，hina； 2. Department of Basic Medical Sciences，Air Force Medical University，Xi’ an 71Oo36，Shaanxi，China）

【Abstract】Doxorubicinisabroad-spectrumantitumordrugwithcleareficacyagainstavarietyofmalignancies，butsevere cardiotoxicityliislcalplicatioprspeoftug.iocodaualityoroltaischdalomeosasislate mitochondrialfunction，andparticipatesimyocadialijuryandepairtoughmitohondrialbogensis，itohondrialaic mitophagySeveaudieshvesotatiochodrialaltyontrolplasaniporatoleinteardiotoxicfectsofdoxobicinut theunderlyingmolecuarmechanismsstllrequirefurtherivestigation.Tisartcleeviesteoleandmechansmofmitochondialuality controlindoxobicinadiotoxicitdsovedinentyars.Iucidateolefitchdialualityotrolindooicin cardiotoxitypovideirectionfoprevetionfdoxorubicin-relatedadotoicidtodentifotetialtapeticaetsfor cardiotoxicity.

【Keywords】 Doxorubicin；Mitochondrial quality control；Cardiotoxicity

阿霉素（doxorubicin，DOX）作為一種療效明確的蒽環(huán)類藥物，被廣泛應(yīng)用于各種惡性腫瘤的治療，如乳腺癌、白血病、霍奇金淋巴瘤等[1]，但1/4的患者出現(xiàn)累積性和劑量依賴性心臟毒性，使該藥物的臨床應(yīng)用受到極大限制[2]。（剩余10928字）